RRA
PLX icon

Round Rock Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Round Rock Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-192,080
Closed -$417K – 337
2026
Q1 		$417K Buy
192,080
+36,978
+24% +$91.8K 0.06% 217
2025
Q4 		$279K Buy
+155,102
New +$317K 0.04% 280

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Round Rock Advisors's PLX Position: Q2 2026 in Review

Round Rock Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 192,080 shares — an estimated $417K sold.

Round Rock Advisors first reported a position in PLX in Q4 2025 and held it in 2 quarters. The position peaked at $417K in Q1 2026. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Round Rock Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
  • Round Rock Advisors sold 192,080 Protalix BioTherapeutics shares in Q2 2026, an estimated $417K.
  • Round Rock Advisors first reported a position in Protalix BioTherapeutics in Q4 2025 and held it in 2 quarters.
  • Round Rock Advisors's Protalix BioTherapeutics position peaked at $417K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.